1383 related articles for article (PubMed ID: 17618847)
21. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
22. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
23. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
24. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
25. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
26. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
27. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
Garnero P; Mulleman D; Munoz F; Sornay-Rendu E; Delmas PD
J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
[TBL] [Abstract][Full Text] [Related]
28. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.
Delmas PD; Marianowski L; Perez Ade C; Ribot C; Pornel B; Palacios S; Lopes P;
Maturitas; 2004 Jun; 48(2):85-96. PubMed ID: 15172082
[TBL] [Abstract][Full Text] [Related]
29. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
30. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
32. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
34. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
35. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
36. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
[TBL] [Abstract][Full Text] [Related]
37. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
[TBL] [Abstract][Full Text] [Related]
38. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
